Brief: Otarmeni Receives EMA Filing Acceptance For Genetic Hearing Loss
22/05/2026 12:01
May 22 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O: OTARMENI™ (LUNSOTOGENE PARVEC) RECEIVES EMA FILING ACCEPTANCE FOR GENETIC HEARING LOSS OTARMENI™ (LUNSOTOGENE PARVEC) RECEIVES EMA FILING ACCEPTANCE FOR GENETIC HEARING LOSS Source text: ID:nGNX90Sx98 Further company coverage: REGN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsLilly, Regeneron selected for US program to review new manufacturing plants faster (updated)
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Brief: Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC
Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)